Orlistat to overcome targeted therapy resistance
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding the weight-loss drug orlistat to your current targeted therapy pill can help overcome resistance and keep the cancer under control. You may qualify if your EGFR-targeted drug has stopped working and you want to stay on it while trying this new combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have taken a third-generation targeted therapy (like osimertinib or lazertinib) and it stopped working
- You are able to get around and take care of yourself (ECOG 0-2)
- Your blood counts and liver/kidney function are within certain safe ranges
- You are willing to keep taking your targeted therapy pill while in the trial
- You do not have serious uncontrolled medical conditions like heart disease or active infections
- You do not have brain metastases that cause symptoms, or a large fluid buildup in your chest or heart sac
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
This study tests whether a targeted therapy pill called osimertinib can work for people whose non-small cell lung cancer came back after they had surgery and completed a course of adjuvant EGFR TKI therapy (like gefitinib or erlotinib). If your cancer has an EGFR mutation and you meet the other health criteria, this trial may offer an additional treatment option.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
Hear when a new Lung Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.